Experts say that the recent market action feels 'more like a repositioning,' and that it won't stop anytime soon.
VIDEO ON MSN MONEY
The company's generics business is poised to grow after it recorded revenue of nearly $10 billion in 2010.
Biopharmaceutical includes primary care, specialty care, established products, emerging markets and oncology units that focus on treatment and prevention of cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, respiratory diseases, urogenital conditions, cancer, eye disease and endocrine disorders, among others. Its diversified unit includes animal health, consumer health and nutritional products such as nutritional supplements and toddler formula products.
Booming foreign interest in domestic reserves creates big opportunity.
The U.S. and Canada are sitting on one of the biggest energy booms ever. An oil and gas production renaissance is under way, thanks to improved hydraulic fracturing and advances in drilling techniques. Though not without controversy, shale formations like the Marcellus, Utica and Eagle Ford have become hotbeds of North American drilling activity because these advances have made it possible to extract the plethora of fossil fuels trapped between the rocks.
With billions of dollars in revenue at stake, these regions have witnessed a land grab not seen since the California Gold Rush of the 1800s. While the usual suspects like Exxon (XOM) are staking their claims, North America's shale interests are getting plenty of attention from overseas sources as well.
Positive action on new drugs by FDA in 2011 bodes well for biopharmaceuticals in 2012, and Celgene can offer long-term growth.
"We see the FDA's modestly raised fiscal 2012 budget supporting continued improvement in the approval of new drugs on first review cycle," says Steven Silver, a biotech analyst at Standard & Poor's. The FDA's approval of new drugs in 2011 jumped 63% after an increase of about 50% in 2010, indicating a much-improved dedication by the FDA in supporting biotech and pharmaceutical companies in their quest for badly needed new drugs, Silver argues.
A recently launched oil and gas trust offers protected payouts and attractive yield.
By Elliott Gue, The Energy Strategist
Chesapeake Granite Wash Trust (CHKR), the newest addition to the universe of U.S. oil and gas trusts, went public on Nov. 11. It is also among the most promising and fastest-growing trusts in my coverage universe.
Diversified holdings in utilities, commodities and transportation sectors offer stable cash flow.
By Gordon Pape, The Canada Report
This will be a year of uncertainty. Since I am a conservative investor by nature, I am selecting a security with limited downside risk, stable assets and good cash flow.
The year has started off well, but some sectors and strategies have the potential to pay off even better in coming weeks.
By Tom Aspray, MoneyShow.com
The first week of the New Year has certainly been a good one for the stock market, as the S&P 500 finished the week up 1.3% and the Dow Industrials gained 1.1%. This was in contrast to the 3.4% gain in the Nasdaq-100.
There was little in the way of bad news from the eurozone (for a change), though yields on many of the euro bonds are still at dangerously high levels. Upcoming bond auctions in euro land will be watched closely.
Major oil producers saw output reduced because of the natural decline in production fields, asset sales and political issues.
Brent prices remained above the $100 per barrel mark for most of the year, driven by an improved economic outlook in the first half of the year and supply concerns in the second half. The year also saw the announcement that ConocoPhillips (COP) would divest its downstream business and focus on upstream exploration and production and unconventional resources such as shale.
Gold miner has production volume, growth projects and seasonal factors in its favor.
By Curtis Hesler, The Professional Timing Service
There was a study done in the 1970’s that revealed that gold stocks tended to bottom in the fourth quarter and rally strongly into the end of the first quarter of the next year. Thus, looking for seasonal bargains in the gold sector makes sense, especially now.
After enjoying months of cheaper fuel, Americans will soon experience more pain at the pump because of oil speculation and market manipulation.
There have been a lot of "funny" things happening in the market over the past two months. I chalk it up to a combination of end-of-year seasonality and a desire by the powers that be to keep the market together long enough to exit ahead of the fall. Something similar happened in 2008 before the most acute phase of the bear market got started.
Wall Street has apparently been using large-cap energy stocks Exxon Mobil (XOM) and Chevron (CVX) to hold the Dow Jones industrial Average aloft, ostensibly to keep retail investors placated so the heavy hitters can create the little upward flurries they need to exit their position. (This has to do with the fact the Dow is a price-weighted index that can be pushed around by the most expensive stocks.)
Pause a moment before you start building an investment strategy based on fourth-quarter reports.
The storage market is rapidly changing in the age of big data and cloud computing.
Even NetApp (NTAP), EMC's only major pureplay storage competitor, saw its stock tumble in the second half of 2011 largely due to concerns of lower government and enterprise spending as the macroeconomic condition deteriorated in the U.S. and Europe.
The biggest letdown is still under the hood.
By Alex Planes
Electric cars started 2011 with a lot of hype and ended the year with a big face-plant. Combined sales for the plug-in electric movement's marquee names, General Motors' (GM) Chevy Volt and the Nissan Leaf, clocked in at fewer than 20,000 units. IDC Energy Insights predicted that half a million plug-ins would sell in 2011, which now seems downright silly.
Don't worry, IDC. You're far from the first to get burned by your love of the electric car.
Sabrient Systems has a strong track record, which is why its annual 'Baker's Dozen' list is getting attention.
Stuff you and I could never fathom.
So when one of the more respected quantitative investment shops releases its stock picks, people pay attention. And when that investment shop becomes known for beating the market year after year with those picks -- well, a lot of people pay attention.
Technical methods identified the strongest and weakest sectors last year, and now they predict the best buying opportunities ahead.
By Tom Aspray, MoneyShow.com
The sector performance in 2011 further illustrates the year’s volatility. Many sectors had a few strong quarters, but the yearly performance numbers do not reflect the wide price swings.
Since the S&P 500 and its tracking exchange-traded fund (ETF) Spyder Trust (SPY) were essentially flat for the year, all the other Select Sector SPDR ETFs, except for Financials (XLF), Materials (XLB), and Industrials (XLI), performed better.
Treatments for myelofibrosis and arthritis could make biotech a takeover target for Big Pharma.
By John McCamant, The Medical technology Stock Letter
Incyte (INCY) is our top stock selection for 2012. The Delaware company is a leader in developing small molecule drugs for cancer and inflammation.
MORE ON MSN MONEY
Copyright © 2014 Microsoft. All rights reserved.
The company complains after the son of Florida State's football coach is televised wearing -- gasp -- Under Armour.
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.
[BRIEFING.COM] The stock market finished a down week on a cautious note with small caps leading the retreat. The Russell 2000 lost 0.5%, widening its weekly decline to 2.6%, while the S&P 500 shed 0.3%. The benchmark index ended the week lower by 2.7%.
This morning, the market was provided a basis to rebound with the July employment report, which was just right for the policy doves (209K versus Briefing.com consensus 220K). It showed payroll growth that was weaker than expected, ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|